Athira Pharma (NASDAQ:ATHA – Get Rating) had its target price cut by Mizuho from $6.00 to $5.00 in a research note released on Monday morning, The Fly reports. Separately, BTIG Research lowered their price target on shares of Athira Pharma from $33.00 to $10.00 and set a buy rating on the stock in a report […]
If broadly covered, Leqembi, the new Alzheimer's drug from Biogen (BIIB) and Eisai (ESALF) (ESAIY), could add $2B - $5B costs to Medicare annually. Read more here.
Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease to focus on 40 mg dose Open label extension trial to be extended, providing up to 36 months of long-term. | May 11, 2023
Athira Pharma (NASDAQ:ATHA – Get Rating) is scheduled to post its quarterly earnings results on Wednesday, May 10th. Athira Pharma Trading Down 3.4 % ATHA opened at $2.86 on Tuesday. Athira Pharma has a 1-year low of $2.22 and a 1-year high of $9.92. The stock has a market capitalization of $108.51 million, a price-to-earnings […]
Athira Pharma (NASDAQ:ATHA – Get Rating) and Exelixis (NASDAQ:EXEL – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Institutional and Insider Ownership 58.7% of Athira Pharma shares are held […]